Endocrine Abstracts

Objectives: Radical prostatectomy is an effective therapy for clinically localized prostate cancer. A significant number of men develops post-prostatectomy erectile dysfunction (PPED), due to surgery-related nervous damage. PPED is relatively refractory to PDE5i therapy. In a rat model of bilateral cavernous neurotomy we evaluated whether chronic tadalafil treatment (CTT) could ameliorate anatomical and functional damage to corpora cavernosa (CC).Methods...

Objectives: Hypogonadism is often associated with diabetes mellitus and both conditions represent major risk factors for erectile dysfunction (ED). The aim of this study was to evaluate the effect of diabetes-induced hypogonadism on ED using two distinct animal models: alloxan-rabbits and streptozotocin (STZ)-rats.Methods: A subgroup of diabetic animals was Testosterone (T) replaced. After 8 weeks from induction of diabetes, erectile function was evaluat...

BXL-628 is a non-hypercalcemic calcitriol analog successfully tested in a phase IIa trial for benign prostate hyperplasia therapy. Because part of low urinary tract symptoms (LUTS) are generated by overactive bladder (OAB) and bladder expresses the calcitriol receptor (VDR), we investigated the BXL-628 effects on bladder contractility and RhoA/ROK signalling activated in OAB, by in vivo (2-weeks; 30 mcg/Kg, Sprague-Dawley, SD, and spontaneously hypertensive rats, SHR) a...